Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Decline Accept
Home › Insider trades › Amphstar Pharmaceuticals, Inc. › Director received an award of 35K AMPH shares Insider trades
Why it stands out Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
All the details
Dates, kept separate
Transaction date Mar 9, 2026
Reporting period Not applicable
Filed with the SEC Mar 11, 2026 Director Grant / award
Context Classification grant award
Code A — grant or award
Planned / mechanical clue Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID 0001743927-26-000008
Filed / recorded
Mar 11, 2026, 10:26 PM UTC
Added to OQRO Oct 6, 2026, 9:54 PM UTC
Data quality Verified: identifiers matched exactly
Issuer Amphastar Pharmaceuticals, Inc.
Reporting person Yakob Liawatidewi
Relationship Director, Officer
Officer title EVP CORP ADMIN CENTER
Table Non-derivative (Table I)
Transaction date Mar 9, 2026
Acquired / disposed Acquired (A)
Shares owned after 124,795
Footnotes from the filing The reported shares are represented by restricted stock units, or RSUs, which vest in four equal annual installments beginning on March 9, 2027.
Around the same time Insider filing
Traded Mar 15 · filed 3 days later
Routine share withholding; mechanical by default.
Insider filing
Traded Mar 15 · filed 2 days later
Routine share withholding; mechanical by default.
Insider filing
Traded Mar 15 · filed 2 days later
Routine share withholding; mechanical by default.
The story around this disclosure Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
Jan 6, 2026 Company filing · Form 8-K · Material agreement, Reg FD Signed an important agreement, and shared information with investors Feb 26, 2026 Company filing · Form 8-K · Results Reported its results Mar 3, 2026 Company filing · Form 8-K · Material agreement Signed an important agreement Mar 3, 2026 Company filing · Form 8-K · Executive change Changed a top executive or board member “On March 3, 2026 (the “Effective Date”), Amphastar Pharmaceuticals, Inc. (“Amphastar” or, the “Company”), entered into executive employment agreements with each of Jacob Liawatidewi, the Company’s Executive Vice President of Corporate Administration Center, Secretary and a member of the board of directors (the “Liawatidewi Employment Agreement”) and Rong Zhou, the Company’s Senior Executive Vice President of…” What came next May 7, 2026 Company filing · Form 8-K · Results Reported its results